APOLLO HOSPITALS ENTER. L vs GLENMARK PHARMACEUTICALS
A side-by-side comparison of APOLLO HOSPITALS ENTER. L (APOLLOHOSP) and GLENMARK PHARMACEUTICALS (GLENMARK) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, GLENMARK PHARMACEUTICALS leads APOLLOHOSP vs GLENMARK on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability04
- Growth11
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
GLENMARK takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
APOLLOHOSP takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 76.2% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
- − ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
- + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 19.4% CAGR over last 5 years"]
- − ["The company has delivered a poor sales growth of 9.19% over past five years.", "Company has a low return on equity of -3.28% over last 3 years.", "Debtor days have increased from 85.2 to 107 days.", "Working capital days have increased from 41.2 days to 80.5 days"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.